Calidi Biotherapeutics, Inc. (NYSE:CLDI - Get Free Report) CEO Allan Camaisa sold 10,000 shares of Calidi Biotherapeutics stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $1.62, for a total transaction of $16,200.00. Following the sale, the chief executive officer now owns 66,712 shares in the company, valued at approximately $108,073.44. This trade represents a 13.04 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Calidi Biotherapeutics Price Performance
Shares of CLDI opened at $1.44 on Thursday. The business's 50-day simple moving average is $1.68. Calidi Biotherapeutics, Inc. has a 12 month low of $0.73 and a 12 month high of $19.70.
Calidi Biotherapeutics (NYSE:CLDI - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.65) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.20. As a group, sell-side analysts anticipate that Calidi Biotherapeutics, Inc. will post -4.48 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Calidi Biotherapeutics
WARNING: “Buffett Indicator” flashing for first time in 50 years
From Behind the Markets | Ad
Warren Buffett has sold a staggering $97 billion worth of stocks this year...
But why?
Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash.
His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.
Take these 4 steps today to protect your retirement NOW
An institutional investor recently raised its position in Calidi Biotherapeutics stock. Delta Investment Management LLC boosted its position in shares of Calidi Biotherapeutics, Inc. (NYSE:CLDI - Free Report) by 1,955.0% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 210,230 shares of the company's stock after purchasing an additional 200,000 shares during the period. Delta Investment Management LLC owned about 0.41% of Calidi Biotherapeutics worth $42,000 at the end of the most recent quarter. Institutional investors own 12.53% of the company's stock.
About Calidi Biotherapeutics
(
Get Free Report)
Calidi Biotherapeutics, Inc, a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
